J o u r n a l P r e -p r o o f Journal Pre-proof Highlights • Activated CD4+ T cells in CSF and plasma cells in blood are increased in NS compared to MS. • The combination of blood and CSF parameters aids distinguishing between NS and MS. • We generated and validated a multi-dimensional model of blood and CSF parameters to discriminate NS from MS. Abstract Distinguishing neurosarcoidosis (NS) from multiple sclerosis (MS) remains challenging and available parameters lack discriminatory power. Comprehensive flow cytometry data of blood and CSF leukocytes of patients with NS (n = 24 ), MS (n = 49) and idiopathic intracranial hypertension (IIH, n = 52) were analyzed by machine learning algorithms. NS featured a specific immune cell pattern with increased activated CD4+ T cells in CSF and increased plasma cells in blood. Combining blood and CSF parameters improved the differentiation. We thereby identify and independently validate a multi-dimensional model of blood and CSF supporting the difficult differential diagnosis between NS and MS. Abbreviations AUC: Area under the curve BBBD: Blood-brain barrier disruption Bc: B cells cMono: classical monocytes EDSS: Expanded Disability Status Scale intMono: intermediate J o u r n a l P r e -p r o o f Journal Pre-proof
Introduction
Sarcoidosis is an inflammatory multisystem disorder featuring epithelioid granulomas in multiple organs (Burns, 2003) . Involvement of the nervous system, then termed neurosarcoidosis (NS), occurs in up to 25% of sarcoidosis patients who undergo autopsy, although only 5-10% of all sarcoidosis patients show clinically apparent neurologic symptoms (Iannuzzi et al., 2007) . In affected patients, NS often causes severe and permanent disability (Joubert et al., 2017) .
Despite extensive research, the pathogenesis of sarcoidosis remains poorly understood.
Multiple studies identified T cells to play a major role in sarcoidosis by revealing a disequilibrium between effector and regulatory T cells (Miyara et al., 2006) and a polarization of CD4+ T cells to a Th1 (Moller et al., 2017) and Th17 effector phenotype (Ramstein et al., 2016) . The T cell-derived cytokines are thought to trigger macrophage accumulation and granulomatous formations (Chen and Moller, 2011) .
Due to the large variety of symptoms, the pre-mortem diagnosis of NS remains challenging (Hoitsma et al., 2004) . Available diagnostic procedures such as ACE, sIL2R, Neopterin, CD4/CD8 ratio suffer from a lack of sensitivity and specificity (Voortman et al., 2019) .Diagnostic criteria for definite neurosarcoidosis require a brain biopsy to be performed (Wegener et al., 2015) , a very invasive procedure. In fact, in up to 74% of cases neurologic involvement precedes the diagnosis of sarcoidosis (Spencer et al., 2005) . Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system (CNS) with autoimmune origin that constitutes a particularly difficult differential diagnosis of NS for multiple reasons: First, the clinical presentations of both diseases overlap. Second, magnetic resonance imaging white matter lesions often remain indistinguishable from MS lesions (Spencer et al., 2005) . Third, CSF can show similar alterations in NS and MS, such as mild pleocytosis (Pawate et al., 2009) . Therefore, improved diagnostic procedures are needed to direct treatment decisions.
Here, we present a comprehensive immune cell profiling of the blood and CSF of NS patients in comparison to MS and control idiopathic intracranial hypertension (IIH) patients. We find that activated CD4+ T cells in the CSF and plasma cells in the blood distinguish NS from MS and controls. We construct an integrated model from these parameters which improves our understanding and may ultimately facilitate diagnosis of NS.
Methods

Participants
We retrospectively analyzed electronic records of patient who were admitted to the Department of Neurology of the University Clinic Münster, Germany between 2012 and 2019. We routinely perform flow cytometry of CSF samples during regular working hours in our center. First, all patients that had received a lumbar puncture (LP) with a flow cytometry analysis and had been assigned ICD-10 diagnosis codes D86.* (sarcoidosis) , G35.1 (relapsing-remitting MS) or G93.2 (IIH) were included (n = 70). Second, we selected patients with sarcoidosis and confirmed CNS involvement and CSF flow cytometry data available and subsequently refer to this cohort as neurosarcoidosis (NS) (n = 24) (Table 1) . MS patients (n J o u r n a l P r e -p r o o f Journal Pre-proof = 49) served as an inflammatory reference group, while control IIH patients (n = 52) usually exhibit normal CSF (Friedman et al., 2013) . NS patients were selected and classified according to the modified Zajicek diagnostic criteria (Marangoni et al., 2006; Zajicek et al., 1999) . Diagnosis certainty was determined 'definite' in 2 NS patients, who had confirmed granulomas in brain biopsy, 'probable' in 8 and 'possible' in 14 patients. Only MS patients that fulfilled the revised McDonald criteria 2017 (Thompson et al., 2018) were included.
Patients who had been treated with alemtuzumab, ocrelizumab, cladribine, or rituximab in the last year or with fingolimod, natalizumab, mitoxantrone, cyclophosphamide, cyclosporin A in the last 3 months were excluded from all cohorts. Current treatments with steroids, azathioprine, methotrexate, glatiramer acetate and dimethyl fumarate were accepted. About half of the NS patients (45.8%) were not treated in the last 12 months, the most common therapy in treated patients was steroids (Table 1 , Fig. S5a ). Gender ratio was comparable between IIH, MS and NS, however, NS patients were significantly older (Table 1) . After model building, we retrospectively identified a cohort of MS (n =155) and NS patients (n = 6). These patients fulfilled the same inclusion criteria as the model building cohorts and were used to test the sensitivity and specificity of the model. 
Flow cytometry
LPs were performed under sterile conditions and CSF was promptly analyzed. CSF was centrifuged at 300 g for 15 min, supernatant was removed and CSF cells were stained with different antibodies as previously described (Gross et al., 2016; Heming et al., 2019) . Briefly, flow cytometry was performed on a Navious flow cytometer (Beckmann Coulter). Cells were incubated in VersaLyse buffer and stained with anti-human antibodies (Beckman Coulter, clone names in brackets): CD3 (UCHT1); CD4 (13B8.2); CD8 (B9.11); CD14 (RMO52); CD16 (3G8); CD19 (J3-119); CD45 (J.33); CD56 (C218); CD138 (B-A38); HLA-DR (Immu-357). First, cells were gated on forward scatter (FSC) / sideward scatter (SSC) and subsequently on CD45+ cells ( Fig. S1 ). We then assessed the percentage of cell population (Robin et al., 2011) . A ROC analysis allows a systematic evaluation of the sensitivity and specificity of a test represented by the area under the curve (AUC) values ranging from an AUC of 0.5 (uninformative) to an AUC of 1 (perfect) (Hanley and McNeil, 1982) . We performed elastic net regularization with logistic regression (Zou and Hastie, 2005) , to generate a multidimensional score. The data were scaled and centered in advance and highly correlated predictors (threshold 0.75) were removed. We reduced the numbers of predictors from 23 to 6 based on feature importance in a first model including all variables.
Next, a model with the remaining 6 predictors was trained to find optimal penalty terms, L1
and L2-norm, resulting in high discriminatory performance as shown by the AUC. This was achieved by using repeated cross-validation (k = 10, n = 300) on the dataset with the R package caret (Kuhn, 2008) . Using these high numbers of repeats, we generated reproducible results despite the small sample size. The interactive model was created with shiny.
Results
Blood shows heterogeneous immune cell activation in NS
We performed immune cell profiling of blood and CSF cells of NS, IIH, and MS patients.
Representative flow cytometry plots for each diagnosis are displayed in Fig. S2 . First we focused on blood analysis. The principal component analysis (PCA) of blood data showed overlap between IIH and MS patients (Fig. 1a) . In contrast, the average of all NS patients was distinct from the two other groups (Fig. 1a ). NS samples were more heterogeneous than the J o u r n a l P r e -p r o o f Journal Pre-proof other groups (Fig. 1a ). This heterogeneity was mainly driven by plasma cells, NK cells, activated CD4+ T cells and monocyte populations in principal component (PC)1 (Fig. S3a ).
In fact, when plotting individual parameters, we found that blood of NS patients exhibited signs of immune cell activation with increased proportions of activated T cell, NK cell, and B lineage cells (Fig. 1b ). Most differences were not statistically significant: only plasma cells and non-classical and intermediate monocytes were significantly increased, while total T cells were decreased in the blood of NS patients (Fig. 1c ).
CSF exhibits distinct immune cell profiles in MS and NS patients
Next, we focused on CSF leukocytes. The CSF of MS and NS patients displayed an immune cell pattern distinct from IIH controls ( Fig. 2a ). The separation between NS/MS vs. IIH was mostly driven by cell count, proteins, lymphocytes, and OCB. (Fig. S3b ). In addition, NS also partially separated from MS (see PC2 in Fig. 2a ) and the most important components of this segregation were CD4 cells, the CD4/CD8 ratio, protein and OCBs (Fig. S3b ). When plotting individual parameters, we found that the CSF of MS patients exhibited a well-known expansion of plasma cells and increase of OCBs and intrathecal Ig synthesis (Alvermann et al., 2014) (Fig. 2b,c ; Table 1 ). This served as a positive control that our approach reproduces known inflammatory changes. In contrast, NS patients featured different inflammatory alterations of CSF, including elevated total cell counts, lymphocytes, protein concentrations and blood-brain barrier disruption (Fig. 2b,c ; Table 1 ). In addition, the CSF of NS patients also showed a significant increase of activated (i.e. HLA-DR+) CD4+ T cells and an increased CD4/CD8 ratio compared to MS (Fig. 2b,c) . In comparison to IIH, NS featured an expansion of NK cells and non-classical monocytes (Fig. 2b,c) . Leukocytes from the B lineages (B cells, plasma cells) were also increased in NS compared to IIH, albeit less prominently than in MS. To be able to directly compare CSF to blood, we also performed J o u r n a l P r e -p r o o f PCA for CSF with the same parameters as in blood, i.e. leaving out parameters that are unique to CSF such as OCB (Fig. S4) . The result is slightly worse than with all CSF parameters included, but still the segregation between NS/MS and IIH remains obvious in CSF compared to blood. CSF is thus superior to blood in the defining NS. In summary, CSF exhibits immune cell alterations in both NS and MS, but NS is characterized by a specific increase of activated T cells, NK cells, and the CD4/CD8 ratio.
Single CSF parameter distinguishes NS from MS with good confidence Distinguishing NS from MS is clinically relevant, but difficult. We therefore next systematically evaluated our findings for NS vs. MS discriminatory ability. We used the AUC of the ROC analysis to quantify the performance of each predictor (Mandrekar, 2010) .
We found that plasma cells were the best blood parameter (AUC 0.68), followed by intermediate monocytes (AUC 0.67) and T cells (AUC 0.67) with some discriminatory power ( Fig. 3a , Table S1 ). In CSF, plasma cells were the top parameter distinguishing NS from MS (0.83), followed by OCBs (0.79) and activated CD4+ T cells (0.73) ( Fig. 3b , Table S2 ). CSF is thus superior to blood in the differential diagnosis of NS. We identified activated CD4+ T cells in CSF as a new surrogate parameter, discriminating between NS and MS. To improve the discriminatory performance between NS and MS further, we combined all blood and CSF parameters. This combination resulted in distinct profiles of MS and NS patients with non-overlapping confidence intervals and reduced intra-disease heterogeneity in NS (Fig. 4a, Fig. S3c ). We therefore created a penalized logistic regression model of combined blood and CSF parameters. The best performing model was defined by the highest AUC and the smallest number of predictors. The resulting multidimensional model (AUC = 0.95) significantly outperformed the best single parameter (AUC = 0.83). In this model, OCBs pointed to the presence of MS (Fig. 4b) 
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Discussion
The pathogenesis of NS is poorly understood and the differentiation from other neuroinflammatory diseases based on clinical and imaging findings remains challenging (Straus Farber et al., 2009 ). In the current study, we identified disease-specific immune cell profiles in NS with increased activated CD4+ T cells in CSF and elevated plasma cells in blood compared to MS. This suggests a pivotal role of these cells in the pathophysiology of NS. In a systematic evaluation of discriminatory ability between NS and MS, we identify for the first time plasma cells in blood and activated CD4 cells in CSF as the best predictors for the presence of NS. The combination of blood and CSF parameters resulted in improved diagnostic capabilities using an integrated model of both compartments which we validated in an independent cohort. CD4+ T cells activation is considered a key step in the pathophysiology of sarcoidosis (Zissel and Müller-Quernheim, 2015) . However, expansion of CD4+ T cells has previously not been reported in CSF of NS patients. We discovered that cytotoxic dim NK and NKT cells were elevated in severely affected NS patients compared to mildly affected NS patients, measured by dichotomized EDSS and mRS (Fig. S5b,c ). However, we found similar pattern in treated NS patients compared to untreated (Fig. S5d) . From a clinical perspective severely affected patients are more likely to be treated. We speculate that cytotoxic cells, such as dim NK cells and NKT cells correlate with disease severity. In NS patients in relapse we observed expansion of lymphocytes and CD4+ T cells and reduction of NKT and CD8+T cells (Fig.   S6a ). A similar pattern could be observed in NS patients with a short disease duration (Fig.   S6b ). Patients with first consultation (short duration) will more likely have an active disease than patients with a follow-up consultation (longer duration) who may be in remission. The J o u r n a l P r e -p r o o f success of B cell-ablative therapy in (neuro)sarcoidosis indicates that this T-cell driven disease also involves B cells (Bomprezzi et al., 2010; Gottenberg et al., 2005) . Plasma cells were found to infiltrate granulomas in affected tissues (Kamphuis et al., 2013) , but we are the first to report an expansion of blood plasma cells. These findings thus support the rationale of B cell-directed therapy in NS on a pathophysiological level.
Our study is limited by the retrospective study design, the small patient cohort including treated patients. However, a prospective study with untreated NS patients, will be very challenging especially since CSF flow cytometry has to be performed immediately. Our study thus constitutes the first in-depth characterization of CSF cells in NS . We here articulate new pathogenetic hypotheses and suggest new potential biomarkers and a multi-dimensional model to distinguish NS from MS that will need further validation in larger, independent patient cohorts. In a small independent validation cohort the performance of our prediction model showed excellent detection of MS and acceptable detection of NS. A further limitation of the model is the pre-selection of flow cytometry markers. However, our choice of flow cytometry markers reflects all major leukocyte lineages. Additionally,multiple papers have developed scores and multi-dimensional models based on pre-selected markers (Galovic et al., 2018; Liu et al., 2017; Schrag et al., 2017) . Nonetheless, we cannot exclude that there are further useful markers to distinguish MS and NS, that we did not investigate and did not include in our model. CSF examination supports the diagnosis of NS (Zajicek et al., 1999) . In line with our findings, common findings are pleocytosis, CSF protein elevation, blood-brain barrier disruption, intrathecal Ig synthesis and presence of OCBs (Hietaharju et al., 1990; Lacomis, 2011; Wengert et al., 2013) . One long-known biomarker is ACE, that is elevated in about 30-J o u r n a l P r e -p r o o f 50% of NS patients (Fritz et al., 2016; Oksanen et al., 1985) and is used in the original version of the Zajicek criteria (Zajicek et al., 1999) . Since ACE is also elevated in CNS infections and malignant tumors (Hoitsma et al., 2004; Oksanen et al., 1985) , it has been suggested to replace increased ACE level by elevated CD4/CD8 ratio (Marangoni et al., 2006) . We here showed that CD4/CD8 ratio performs worse in differentiating NS from MS than activated CD4+ T cells. A few years ago, sIL2-R in CSF was introduced as a new biomarker in NS with a sensitivity of 61 and specificity of 93% compared to other inflammatory diseases of the CNS (Petereit et al., 2010) or healthy control. A drawback of sIL2-R is that infectious diseases of the CNS also show elevated sIL2-R levels (Petereit et al., 2010) . Recently, the use of multiple CSF biomarkers has shown to provide accurate predictions for example in Parkinson's disease (Parnetti et al., 2019) . Our computational model used CSF and blood parameters. First, blood flow cytometry should thus be considered in NS cases and second, the combination of multiple CSF and blood parameters improves the overall diagnostic accuracy in neuroinflammation. Multi-compartment models thus present potential novel diagnostic tools in a wide range of diseases. The rapid progress in machinelearning allows the generation of complex multi-dimensional models that might outperform established single biomarkers in future.
Conclusion
Differentiating NS from other inflammatory CNS diseases, especially MS, is challenging. We here propose that comprehensive immune cell profiling of blood and CSF helps to the understanding of NS and the discrimination of NS against other diseases including MS.
Diagnostic accuracy can be considerably improved by using a multi-dimensional and crosscompartment model of flow cytometry parameters.
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Supplementary Material
Fig. S1: Pseudocolor plots depict the gating process. Cells of either blood or CSF were gated on forward scatter (FSC) sideward scatter (SSC) or the indicated markers to identify different cell populations as shown. Further outliers are marked as dots. The ellipses around the group mean display the confidence areas. b Blood and CSF data were scaled and centered and highly correlated parameters were removed. An elastic net regularization with logistic regression was generated with the remaining parameters. The model was trained with repeated cross-validation (k = 10, n = 300) to find optimal penalty terms and an optimal number of 6 predictors was determined. 
